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Abstract
Chromosomal translocations in tumors frequently produce fusion genes coding for chimeric proteins with a key role in
oncogenesis. Recent reports described a BCR-JAK2 fusion gene in fatal chronic and acute myeloid leukemia, but the
functional behavior of the chimeric protein remains uncharacterized. We used fluorescence in situ hybridization and reverse
transcription polymerase chain reaction (RT-PCR) assays to describe a BCR-JAK2 fusion gene from a patient with acute
lymphoblastic leukemia. The patient has been in complete remission for six years following treatment and autologous
transplantation, and minimal residual disease was monitored by real-time RT-PCR. BCR-JAK2 codes for a protein containing
the BCR oligomerization domain fused to the JAK2 tyrosine-kinase domain. In vitro analysis of transfected cells showed that
BCR-JAK2 is located in the cytoplasm. Transduction of hematopoietic Ba/F3 cells with retroviral vectors carrying BCR-JAK2
induced IL-3-independent cell growth, constitutive activation of the chimeric protein as well as STAT5 phosphorylation and
translocation to the nuclei, where Bcl-xL gene expression was elicited. Primary mouse progenitor cells transduced with BCR-
JAK2 also showed increased proliferation and survival. Treatment with the JAK2 inhibitor TG101209 abrogated BCR-JAK2
and STAT5 phosphorylation, decreased Bcl-xL expression and triggered apoptosis of transformed Ba/F3 cells. Therefore,
BCR-JAK2 is a novel tyrosine-kinase with transforming activity. It deregulates growth factor-dependent proliferation and cell
survival, which can be abrogated by the TG101209 inhibitor. Moreover, transformed Ba/F3 cells developed tumors when
injected subcutaneously into nude mice, thus proving the tumorigenic capacity of BCR-JAK2 in vivo. Together these findings
suggest that adult and pediatric patients with BCR-ABL-negative leukemia and JAK2 overexpression may benefit from
targeted therapies.
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Introduction
Acute lymphoblastic leukemia (ALL) is a malignant disease
characterized by the clonal expansion of lymphoid progenitors. Out-
come is poorer in adults than in children, probably due to the
higher frequency of Philadelphia (Ph’) chromosome–positive ALL
[1]. The Ph’ chromosome results from a translocation, t(9;22)
(q34;q11), which leads to the BCR-ABL fusion gene. One-third of
adult ALL patients with the Ph’ chromosome show major (M)-BCR
rearrangements (resulting in a 210-kDa protein), whereas two-thirds
have minor (m)-BCR rearrangements (resulting in a 190-kDa
protein). These chimeric proteins are hyperactive tyrosine kinases
(TK) that are located in the cytoplasm, where they recruit
downstream effectors of cell proliferation and survival. Chromosomal
rearrangements other than t(9;22)(q34;q11) are found in ALL,
although they are less frequent (http://AtlasGeneticsOncology.org).
JAK2 is a non-receptor TK protein that is essential for signaling
through a variety of cytokine receptors and is required for normal
hematopoiesis [2,3]. Activation of the JAK2-cytokine receptor
complex leads to the recruitment and JAK2-mediated phosphor-
ylation of STAT5 proteins whose subsequent dimerization and
nuclear translocation induces target gene transcription [4]. The
role of constitutively activated JAK2 or STAT5 in cellular
transformation has been established [5]. Several fusion proteins
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involving the catalytic active JH1 domain of JAK2 have been
reported to be associated with leukemia, as follows: 1) TEL-JAK2
was found in both pre-B-lineage and pre-T-lineage ALL and
atypical chronic myelogenous leukemia (CML) [6,7] 2) PCM1-JAK2
gene fusion resulting from t(8;9)(p22;p24) in eosinophilia-associated
atypical CML, ALL, acute myeloid leukemia (AML), and T cell
lymphoma [8], and 3) BCR-JAK2 gene fusion as the result of
t(9;22)(p24;q11) was found in atypical CML [9,10] and AML [11].
Other putative JAK2 translocations include SSBP2-JAK2 in pre-B
ALL [12], PAX5- and STRN3-JAK2 in childhood ALL [13] and
SEC31A-JAK2 in classical non Hodgkin lymphoma [14]. Moreover,
gain-of-function JAK2 mutations are common in myeloproliferative
neoplasms [15] and in up to 15% of adult and high-risk pediatric B-
ALL lacking MLL, TCF3, TEL and BCR-ABL rearrangements
[16,17,18]. These observations have supported the search for
selective inhibitors of JAK2 [19,20] and several compounds are
currently undergoing clinical trials for myelofibrosis [21,22]. Here
we provide for the first time evidence of the transforming and
tumorigenic activity of JAK2 through fusion with BCR.
Materials and Methods
Ethics Statement
Patient written informed consent was obtained before bone
marrow biopsies were taken. This protocol was carried out according
to current Spanish legislation on clinical research in humans and was
approved by the Hospital Universitario de la Princesa Clinical
Investigation Ethics Committee (Approval ID: PI-424).
All experimentation with mice was carried out in accordance
with institutional guidelines from the animal care and use
committee from Centro de Investigaciones Tecnolo´gicas y Med-
ioambientales (CIEMAT) and approved by them with approval ID:
HEM 4-09.
Case description
A 58-year-old male presented with asthenia, abdominal pain and
slight hepatosplenomegaly. The blood count was abnormal with
anemia of Hb 10.9 g/dl and a platelet count of 416103/mm3. The
white blood cell count was 10.86103/mm3 with 38% lymphocytes,
6% monocytes, 4% myelocytes and metamyelocytes, and 58% small
lymphoblasts. Immunophenotyping of bone marrow disclosed B-
lineage lymphoblasts (CD34+, CD19+, CD10+, MPO2, CD79a+,
HLA-DR+, Tdt+, CD22+, and CD24+). Karyotyping performed on
the marrow aspirate revealed 49,XY,+X,+2,+4,29,211,+19,-
add(19)(q13),+20,222,+mar in 24 of 25 metaphases examined.
BCR-ABL and MLL rearrangements were not detected by standard
fluorescence in situ hybridization (FISH). While reverse transcriptase
polymerase chain reaction (RT-PCR) analyses for BCR-ABL
rearrangements were negative, we found a new BCR-JAK2
transcript. The patient was diagnosed with ALL and started a
standard high-risk ALL protocol. Hematologic, cytogenetic, and
complete molecular remission (CMR) was achieved after five weeks,
and the treatment proceeded through four standard consolidation
cycles followed by an autologous peripheral blood stem cell
transplant (SCT) with cyclophosphamide and total body irradiation
(12 Gy). Low-dose interferon alpha was administered for five
months as maintenance antileukemia therapy. More than six years
later, the patient remains in complete remission.
RT-PCR and real-time PCR
Total RNA was isolated using Ultraspec (Biotecx, Houston,
TX, USA) and reverse transcribed using the Gene-Amp Gold
RNA PCR Core Kit (Applied Biosystems, Cheshire, UK). PCR
for BCR-ABL p190 was carried out according to [23]. BCR-B
and JAK2-3 primers were used for BCR-JAK2 qualitative PCR
(Table 1). Long-range PCR to amplify full-length BCR-JAK2
cDNA was performed using the GC-RICH PCR System (Roche
Diagnostics, Basel, Switzerland) with BCR-Fw-T and JAK2-Rv-T
primers. The PCR product was cloned in PCR2.1-TOPO
(Invitrogen, Carlsbad, CA, USA) and sequenced using the d-
rhodamine terminator cycle sequencing kit and an ABI PRISM 337
DNA sequencer (Applied-Biosystems). Sequences were aligned
using BLAST and ClustalW applications (http://searchlauncher.
bcm.tmc.edu/). BCR-JAK2 was quantified using fluorescence
resonance energy transfer (FRET)-hybridization probes designed
by TibMolbiol (Berlin, Germany) and hybridized to a BCR
sequence upstream of the BCR-JAK2 breakpoint by means of
BCR-B and JAK2-3 primers. The PCR master mix was prepared
with 0.3 mM of each primer and probe using LightCycler FastStart
DNA MasterPLUS HybProbe (Roche Diagnostics), and the reaction
was performed in duplicate on a LightCycler 2.0 (Roche
Diagnostics). Data were normalized using BCR levels in the
same samples. Quantitative PCR (qPCR) for Bcl-xL, Osm was
performed using the LightCycler FastStart DNA Master SYBR
Green I kit (Roche Diagnostics) and Socs2 (NM_007706) expression
was analysed using RT2 qPCR primer assay (SABiosciences,
Frederik, MD, USA) following the manufacturer’s protocols.
Data were normalized using H3 (patient sample) or Gapdh (Ba/F3
cells) levels.
Fluorescence in situ hybridization
FISH was performed on bone marrow interphase nuclei using a
probe set for BCR (LSIH 22 BCR Spectrum GreenTM; Vysis,
Downers Grove, IL, USA) and bacterial artificial chromosome
(BAC) clone flanking probes covering the whole JAK2 gene (see
probe’s names and locations in Figure 1, E–G). JAK2 clone
positions were based on data provided by the University of
California–Santa Cruz Genome Browser (http://genome.ucsc.
edu) version hg18 (March 2006). BAC clones were obtained from
the BACPAC Resource Center at the Children’s Hospital
(Oakland, CA, USA) and from the Sanger Institute Mapping
Core Group at The Wellcome Trust Sanger Institute (Hinxton,
United Kingdom) (http://cancerres.aacrjournals.org). BAC DNA
was isolated from 5-ml cultures using a standard miniprep
procedure (PhasePrepTM BAC DNA Kit, Sigma-Aldrich, St.
Louis, MO, USA) and labelled by nick translation with Spectrum-
Green-dUTP and SpectrumOrange-dUTP (Vysis). FISH was
performed according to standard procedures. In all experiments,
100–150 interphase nuclei were scored, and no metaphases were
observed.
Cell lines and reagents
HEK293T cells (ATCC) were cultured in DMEM (Cambrex,
East Rutherford, NJ, USA) containing 10% fetal calf serum,
100 U/ml penicillin, 100 mg/ml streptomycin, 50 mg/ml genta-
micin and 4 mM L-glutamine at 37uC and 5% CO2. Murine Ba/
F3 pro-B cells (ATCC) were grown in DMEM with 10 ng/ml of
recombinant IL-3 (R&D, Minneapolis, MN, USA). Cytokine-
independent Ba/F3 cells transduced with TEL-JAK2 were a gift
from Dr. G. Reuther (Florida University, Tampa, USA). JAK2
inhibitor TG101209 was provided by Dr. Fuller (TargeGen Inc.,
San Diego, CA, USA). Stock solutions were prepared in
dimethylsulfoxide (DMSO).
DNA constructs and retroviral vectors
For expression in HEK293T cells, BCR-JAK2 cDNA was sub-
cloned into the expression vector pcDNA3.1 (Invitrogen) through an
EcoR I site. For retroviral infections in Ba/F3 cells, cDNA was cloned
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into the EcoR I site of the pLZR CMV-IRES-EGFP (pLZR) vector
(Dr. Bernad, Centro Nacional de Investigaciones Cardiovasculares,
Madrid, Spain) to obtain the pLZR-BJ-IRES-EGFP (pLZR-BJ)
vector. The pLZR vector was used as a control. All constructs were
verified by DNA sequencing.
Cell transfections, retrovirus production, infection, and
proliferative assays
Transient transfections in HEK293T cells were performed
with 3 mg of plasmid in Opti-MEM (Lonza, Basel, Switzerland)
using Lipofectin (Invitrogen) according to the manufacturer’s
instructions and analyzed 48 h later. For Ba/F3 cell infection,
retroviral supernatants were obtained as previously described
[24] after transient transfection of Nxe cells with 10 mg of the
pLZR vector bearing or not BCR-JAK2. At 24 and 48 h post-
transfection, viral supernatants were harvested, filtered, and
stored at 280uC. Ba/F3 cells were infected with retroviral
supernatants preloaded four times during 30 min in Retronectin
(12.5 mg/ml, Takara Bio Inc., Shiga, Japan)-coated plates. After
7 days, EGFP+ cells were sorted by flow cytometry using a
FACSAria cytometer (Becton-Dickinson, Franklin Lanes, NJ,
USA). For proliferative assays, 36105 cells of Ba/F3-mock or Ba/
F3-BJ cells were cultured with or without IL-3 (10 ng/ml) on 24-
well plates and counted daily by trypan blue exclusion.
TG101209 dose-dependent kinetic assays were performed as
described [19]. Lineage negative (Lin-) progenitor cells were
selected from male Balb/c mice. Total bone marrow cells
obtained by perfusion of tibiae and femur with IMDM medium
(Invitrogen) were counted and negatively selected by MACS
Lineage Cell Depletion Kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) following manufacturer instructions. Lin- cells were
prestimulated during 48 h (100 ng/ml mSCF, 100 ng/ml hIL-11)
as previously described [25] and seeded in retronectin-coated 6-
well plates for retroviral transduction either with pLZR (mock) or
pLZR-BJ particles. Two cycles of retroviral transduction with a
multiplicity of infection of 50 virus/cell were conducted, and cells
were finally washed and seeded in 6-well plates at 56104 cells/ml
for in vitro expansion. Cells were counted by trypan blue
exclusion every week during 30 days.
Immunofluorescence
See Methods S1.
Western blot analysis
Cells were treated with lysis buffer (0.1 M Tris pH 8, 0.3 M
NaCl, 2% NP-40, 1X EDTA-free Protease Inhibitor Cocktail and
1X PhosSTOP Phosphatase Inhibitor Cocktail [Roche]). Whole
cell lysates (50 mg) or anti-phosphotyrosine immunoprecipitates
(pTyr, BD Biosciences) (500 mg) were resolved by SDS-PAGE
under reducing conditions and blotted with the following
antibodies (Ab’s): anti-JAK2, anti-p-STAT5 (Cell Signaling,
Beverly, CA, USA), anti-STAT5, anti- IkBa (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-Bcl-xL (BD Biosci-
ences), anti-tubulin (Sigma-Aldrich), anti-TBP (Abcam, Cam-
bridge, UK) and secondary HRP-conjugated anti-mouse/anti-
rabbit antibodies (GE Healthcare, Bucks, UK). Enriched nuclear
Table 1. Primers and probes used for PCR analysis.
PCR
Gene
sequence Name 59- 39
Annealing
temperature (6C) Cycles
Product
size (bp) Position (nt)
Qualitative BCR-JAK2 BCR-Fw-T GCCATGGTGGACCCGGTGG 55 35 2260 594–6121
JAK2-Rv-T AAGGTCATTTCTTTCATCCAGCC 3884–39062
Quantitative BCR-JAK2 FRET-probe-FL GTCTTGCGGACGCCCACGA-FL * 1211–12291
FRET-probe-LC640 LC640-GGTGGCCTCGGACACGACAACC+ 1188–12091
BCR-B-Fw CCCCCGGAGTTTTGAGGATTG 63 45 997 1547–15671
JAK2-3-Rv GGCCACAGAAAACTTGCTCTC 3576–35962
BCR BCR-B-Fw CCCCCGGAGTTTTGAGGATTG 63 45 301 1547–15671
BCR-B-Rv ATCGTTGGGCCAGATCTGCC 1828–18471
Bcl-xL Bcl-xL Fw TCAGAGCTTTGAGCAGGTAGTG 58 45 187 726–7473 552–5734
Bcl-xL Rv TCCCGTAGAGATCCACAAAAG 935–9553 761–7814
Osm Osm Fw AGAATCAGGCGAACCTCACGG 58 45 74 217–2375
Osm Rv GTGTGTTCAGGTTTTGGAGGC 271–2915
Gapdh Gapdh Fw AGAAGGTGGTGAAGCAGGCATC 58 45 116 820–8416
Gapdh Rv CGGCATCGAAGGTGGAAGAGTG 915–9366
H3 H3 Fw AAAGCCGCTCGCAAGAGTGCG 62 35 201 185–2057
H3 Rv ACTTGCCTCCTGCAAAGCAC 387–4067
Fw, forward; Rv, reverse; FL, fluorescein; LC640, LightCycler Red.
*,+: inverse and complementary probe sequences to human BCR;
1human BCR (NM_004327);
2human JAK2 (NM_ 004972);
3human Bcl-xL (BCLXL or BCL2L1) (NM_ 1385781);
4mouse Bcl-xL (BCL2-like 1 or Bcl2l1) (NM_ 009743) and
5mouse Osm (oncostatin M) (NM_001013365.2) [39];
6mouse Gapdh (glyceraldehyde-3-phosphate dehydrogenase) NM_008084.2),
7human H3 (H3F3A) (NM_002107.3).
Primers for Bcl-xL and H3F3A are designed to hybridize with both human and mouse sequences (patient samples and Ba/F3 cells, respectively).
doi:10.1371/journal.pone.0032451.t001
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and cytoplasmic extracts were obtained using an NE-PER
extraction reagents kit (Thermo Scientific, Rockford, IL) after
10 min of cold hypotonic shock in 10 mM NaCl. Western blots
were visualized using SuperSignal West Pico Chemiluminescent
Reagent (Thermo Scientific). Densitometry was performed using
Image-Gauge v3.46 software (FujiFilm, Tokyo, Japan).
Figure 1. Cloning and identification of BCR-JAK2 fusion gene. (a) Nested RT-PCR analysis with standard primers for p190 BCR-ABL
amplification (BCR-B and ABL3) on the ALL patient’s samples at diagnosis (PB, peripheral blood; BM, bone marrow) showing an unexpected PCR
product of 281 bp. PC: positive control (BCR-ABL+ p190); NC, healthy negative control. (b) Verification of the BCR-JAK2 fusion gene by RT-PCR analysis
using primers for BCR (BCR-B) and for the region flanking the stop codon of JAK2 (JAK2-Rv-T). NC, BCR-ABL+ p210; MW, molecular weight marker. The
1,370-bp product contains part of BCR exon 1 fused to exon 19 of JAK2 tyrosine-kinase. (c) Full-length BCR-JAK2 cDNA amplification. RT-PCR with
primers extending the start codon of BCR and the stop codon of JAK2. (d) Schematic diagram of the putative BCR-JAK2 fusion protein (strips
represent the fragment of the JAK2 domain JH2). Nucleotide (nt) and amino acid (aa) sequences below showed the BCR-JAK2 breakpoint region (red
lettering represents the common BCR and JAK2 triplet). Numbers indicate the nucleotide breakpoint position: 1767 for the BCR gene (NM_004327)
and 2929 for JAK2 (NM_004972). (e) Interphase nuclei of bone marrow cells at diagnosis after FISH analysis with a probe extending the 59 region of
BCR, showing three green signals indicating a translocation affecting one BCR allele. Schematic BCR gene structure and probe localization are
represented below the nuclei. (f) FISH analysis with BAC probes flanking JAK2. Co-localized green and red signals correspond to the normal JAK2
copy. Rearranged JAK2 allele is detected in the patient’s nucleus as single green and red signals. (g) FISH analysis for BCR-JAK2 translocation. Two BCR
(green) and two JAK2 (red) signals were observed in the control, whereas three BCR signals were detected in the patient, one of them fused with one
red signal, revealing fusion between BCR and JAK2. (h) BCR-JAK2 qPCR. Specific FRET-hybridization probes were used. Arbitrary values for BCR-JAK2
transcripts from diagnosis up to the present time are represented. Data were normalized with BCR. Molecular response was achieved before SCT. BM,
bone marrow; PB, peripheral blood.
doi:10.1371/journal.pone.0032451.g001
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Luciferase reporter assay
See Methods S1.
Apoptosis analysis by flow cytometry
Apoptosis was measured by the binding of Annexin-V and
the incorporation of 7-amino-actinomycin D (7-AAD) after
treatment with the inhibitors. Cells were washed twice with cold
PBS and then resuspended in 1X Binding Buffer (BD Biosciences)
at a concentration of 16106 cells/ml. Staining with annexin V-
phycoerythrin (PE) and 7-AAD was performed following the
manufacturer’s instructions (BD Biosciences). Samples were
analyzed through flow cytometry using an EPICS XL cytometer
(Beckman Coulter, Fullerman, CA, USA).
Tumorigenicity assays in nude mice
Ten female BALB/c OlaHsd-Foxn1nu/nu mice (Harlan Labo-
ratories Inc., Indianapolis, IN, USA) were subcutaneously injected
with 107 Ba/F3 cells expressing BCR-JAK2 together with EGFP
(right flank) and 107 Ba/F3-mock cells expressing only EGFP (left
flank). Mice were examined by palpation for tumor formation for
up to 20 days and then sacrificed by cervical dislocation and
analyzed in a 2000-MM Image Station (Kodak, Rochester, NY,
USA) to detect an EGFP signal. Tumors were extracted and
disaggregated with 20 mg/ml of collagenase IMDM (Sigma-
Aldrich) for 4 h prior to RNA extraction or flow cytometry
analysis in an EPICS XL (Beckman Coulter).
Results
BCR-JAK2 fusion gene identification and real–time PCR
analysis for minimal residual disease follow–up
Standard RT-PCR was performed to detect BCR-ABL using
RNA from bone marrow and peripheral blood samples at
diagnosis. The result for the M-BCR-ABL breakpoint region was
negative (data not shown), but for m-BCR-ABL the reaction
revealed a smaller product compared with the positive control
(Figure 1A). Sequence analysis revealed that this in-frame product
corresponded to the expected BCR exon 1 region, which is usually
found in the p190 BCR-ABL transcript fused to 90 bp correspond-
ing to JAK2 exon 19 and flanked by the ABL reverse primer
(ABL3) (Figure S1). In line with the results of recent cases of CML
[9,10] and AML [11], these data suggested the presence of a BCR-
JAK2 fusion gene. RT-PCR assays were performed on the same
samples (Figure 1B) with primers for BCR (BCR-B) and the stop
codon of JAK2 (JAK2-Rv-T, see Table 1). A specific band of
1,307 bp was obtained and sequenced, containing BCR and the
TK domain of JAK2. The full-length BCR-JAK2 cDNA was
amplified using primers flanking the start codon of BCR (BCR-Fw-
T) and the stop codon of JAK2 (JAK2-Rv-T). A specific band of
2,260-bp was obtained (Figure 1C), sequenced and subcloned. The
complete cDNA encoded a putative 749 amino acid polypeptide
with a predicted molecular mass of 83 kDa that contained the N-
terminal coiled-coil domain of BCR followed by the TK domain of
JAK2 (JH1) (Figure 1D).
An additional FISH analysis was performed (Figure 1E–G).
Using a 300-kb green probe extending the 59 BCR gene region, 3
signals were detected in 73 of 100 nuclei scored, suggesting that
one BCR allele is broken (Figure 1E). In addition, when specific 59
red and 39 green JAK2 flanking probes were used, three signals
were observed in 62 of 101 nuclei scored: one co-localized green-
red signal corresponding to the normal gene copy, and one red
signal and one green signal, suggesting a breakpoint within the
JAK2 locus (Figure 1F). Finally, hybridization with a green probe
for BCR and a red probe for JAK2 showed three green and two red
signals. One of the green split signals was fused with one red signal,
revealing a fusion between the BCR and JAK2 genes in 62 out of
150 (41.3%) nuclei scored (Figure 1G). A specific BCR-JAK2 real-
time PCR assay was designed for follow-up of minimal residual
disease (MRD). The patient acquired CMR five weeks after
induction therapy and prior to SCT, and CMR was maintained to
the present time (more than six years) (Figure 1H).
Ectopic expression of BCR-JAK2 renders hematopoietic
cells growth factor–independent
To investigate the transforming potential of BCR-JAK2, the
interleukin-3 (IL-3)-dependent Ba/F3 cell line was used as a model
[26] and transduced with the pLZR-IRES-EGFP retroviral vector
containing BCR-JAK2 cDNA (Ba/F3-BCR-JAK2) or the control
vector (Ba/F3-mock). As a consequence of BCR-JAK2 expression,
IL-3-independent Ba/F3 cells were obtained after 2–4 days of
culture, yet no independent cells were obtained with the control
vector. Interestingly, Ba/F3-BCR-JAK2 cells showed a cluster-
forming growth pattern when compared to Ba/F3-mock cells
(Figure 2A). Proliferative assays were developed with Ba/F3-BCR-
JAK2 and Ba/F3-mock cells growing either in the presence or
absence of IL-3 (Figure 2B). Ba/F3-BCR-JAK2 cells proliferated
at a comparable rate in both conditions and this rate was even
higher than Ba/F3-mock cells growing with IL-3. Cytokine-
independent Ba/F3 cells transduced with TEL-JAK2 were used as
a positive control because of its in vitro transforming ability
[27,28]. These data suggest that BCR-JAK2 conferred a
proliferative advantage and transformed hematopoietic cells in a
Figure 2. BCR-JAK2 renders Ba/F3 cells growth factor-indepen-
dent. Ba/F3 cells were transduced in three independent experiments
with pLZR-IRES-EGFP (pLZR) retroviral vector alone (Ba/F3-mock) or
pLZR carrying BCR-JAK2 (Ba/F3-BCR-JAK2). Ba/F3 cells transduced with
TEL-JAK2 were used as positive control (Ba/F3-TEL-JAK2). (a) Micropho-
tographs of cultured Ba/F3-mock growing with IL-3 and Ba/F3-BCR-
JAK2 and Ba/F3-TEL-JAK2 cells without IL-3 (620 magnification). (b) For
proliferation assays, 36105 cells were incubated in the presence or
absence of 10 ng/ml IL-3 for 5 days. Viable cells were counted daily by
trypan blue exclusion. Ba/F3-BCR-JAK2 cells proliferate either in the
presence or absence of IL-3. Results are given as mean 6 SD (n = 3).
doi:10.1371/journal.pone.0032451.g002
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similar way to TEL-JAK2 and other BCR-TK chimeric proteins
such as BCR-ABL, BCR-PDGFRA, or BCR-FGFR1 [29,30,31].
BCR-JAK2 is constitutively phosphorylated, triggering
STAT5 activation which translocates to the nucleus and
induces target gene expression on transduced Ba/F3 cells
To test whether Ba/F3 cells stably transduced with pLZR-BJ
expressed tyrosine-phosphorylated BCR-JAK2 and activated
STAT5, cellular lysates were immunoprecipitated with anti-pTyr
Ab and immunoblotted with anti-JAK2 to detect pJAK2. A
tyrosine-phosphorylated product of approximately 90 kDa corre-
sponding to the chimeric protein was detected in Ba/F3-BCR-
JAK2 cells, whereas no such product was seen in Ba/F3-mock cells
(Figure 3A). Therefore, BCR-JAK2, as TEL-JAK2 [6], was
expressed and constitutively phosphorylated on transduced cells.
It is worth noting that TEL-JAK2 protein expression is higher
than BCR-JAK2 in transduced-Ba/F3 cells and this could explain
their higher growth rate depicted in figure 2B. To investigate
whether BCR-JAK2 induced STAT5 activation, Western blot was
performed using anti-pSTAT5 and anti-STAT5 Ab’s, revealing
STAT5 phosphorylation in all Ba/F3 cells tested, with increased
p-STAT5 levels in Ba/F3-mock cells growing with IL-3 and Ba/
F3-BCR-JAK2 and -TEL-JAK2 transduced cells (Figure 3A).
When enriched cytoplasmic and nuclear fractions from total cell
lysates were isolated, pSTAT5 was detected in the enriched
nuclear fraction of these three cell types, suggesting functional
STAT5 activation (Figure 3B). To investigate the subcellular
localization of BCR-JAK2, transiently transfected HEK293T cells
were analyzed by immunofluorescence with anti-JAK2 Ab. No
signal was detected on HEK293T-mock cells, whereas HEK293T-
BCR-JAK2 transfected cells showed intense staining for JAK2 in
the cytoplasm (Figure S2). Taken together, these results suggest
that BCR-JAK2 is located in the cytoplasm and induces cytokine-
independent STAT5 phosphorylation and translocation into the
nucleus.
To demonstrate STAT5 biological activity, qPCR of Bcl-xL
gene expression was performed on transduced Ba/F3 cells
(Figure 3C), given its upregulation upon STAT5 activation in
Figure 3. BCR-JAK2 is constitutively phosphorylated, triggering STAT5 activation which translocates to the nucleus and induces
STAT5 target gene expression on transduced Ba/F3 cells. (a) Western blot analysis of Ba/F3 cells infected with BCR-JAK2, TEL-JAK2 or vector
alone (mock). Cellular lysates were immunoprecipitated with anti-pTyr Ab and immunoblotted with anti-JAK2 Ab to see pJAK2 (upper panel:
endogenous JAK2: 130 kDa, BCR-JAK2: 90 kDa, TEL-JAK2: 72 kDa). TEL-JAK2 protein expression is higher than BCR-JAK2 in transduced Ba/F3 cells.
Whole cell lysates were probed with anti-pSTAT5 and anti-STAT5 Ab’s (bottom). The expression levels of Tubulin were used as a loading control. (b)
Enriched cytoplasmic (C) and nuclear (N) extracts from Ba/F3-mock,Ba/F3-BCR-JAK2 and Ba/F3-TEL-JAK2 cells were prepared from total cell lysates
and blotted with anti-pSTAT5 Ab. TATA-Binding protein (TBP) and IkBa were used as loading controls for enriched nuclear and cytoplasmic fractions,
respectively. (c) Expression of Bcl-xL, Osm and Socs2 in Ba/F3-mock, Ba/F3-BCR-JAK2 and Ba/F3-TEL-JAK2 cells by qPCR. For comparative purposes,
mRNA levels in untreated cells were normalized to 1. Bars represent fold changes of each gene normalized using GADPH levels. Results are given as
mean 6 SEM (n = 3).
doi:10.1371/journal.pone.0032451.g003
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response to cytokines [32,33,34] and leukemic fusion proteins
[35,36]. Two to three-fold upregulation in Bcl-xL expression was
detected in Ba/F3-BCR-JAK2 and Ba/F3-mock cells growing
with IL-3 suggesting cytokine-independent BCR-JAK2-mediated
upregulation of Bcl-xL. Moreover, the quantification of Bcl-xL
using RNA from the patient sample at diagnosis revealed
increased expression of this gene compared with samples in
CMR (Figure S3). In addition, luciferase reporter assays in
HEK293T-BJ cells co-transfected with a plasmid bearing the
promoter region of Bcl-xL containing a STAT binding element
showed that BCR-JAK2 induced Bcl-xL promoter activation
(Figure S4). As expected, HEK293T-mock cells were unable to
induce Bcl-xL activation, whereas HEK293T cells transfected with
a constitutively active STAT5 construct showed enhanced Bcl-xL
activation. Therefore, we conclude that BCR-JAK2 elicited Bcl-xL
promoter activation.
In addition to Bcl-xL expression, we have investigated other
STAT5 target genes as oncostatin M (Osm) and suppressor of
cytokine signaling-2 (Socs2) [27,37,38,39] (Figure 3C). As expected,
both genes had increased expression in Ba/F3-BCR-JAK2, TEL-
JAK2 [27] and mock cells growing with IL-3.
TG101209 abrogated BCR-JAK2 activation and STAT5
phosphorylation leading to downregulation of STAT5
target gene transcription
TG101209 is a potent and selective inhibitor of JAK2
(IC50 = 6 nM) that induces cell cycle arrest and apoptosis in Ba/
F3 cells expressing the JAK2V617F mutation (IC50 = 170 nM) and
in JAK2V617F-expressing acute myeloid leukemia cells through
the inhibition of pJAK2V617F and pSTAT5 [19]. Therefore, Ba/
F3 cells expressing BCR-JAK2, TEL-JAK2 or Ba/F3-mock cells
were treated with TG101209 for 12 h and compared with the
vehicle DMSO-treated cells. To analyze cell viability, dose-
dependent kinetic assays were performed and 1 mM TG101209
dose was selected (Fig. 4A). Interestingly, this assay revealed a
higher susceptibility of Ba/F3-BCR-JAK2 and Ba/F3-TEL-JAK2
cells to TG101209 compared with Ba/F3-JAK2V617F cells [19].
Cellular lysates were immunoprecipitated with anti-pTyr Ab and
immunoblotted with anti-JAK2 to detect pJAK2 (Figure 4B, upper
panel). Densitometry analysis revealed a 76% inhibition rate of
BCR-JAK2 phosphorylation at 12 h of treatment compared to
10% inhibition of pTEL-JAK2 but this could be due to the higher
TEL-JAK2 expression. Endogenous JAK2 phosphorylation was
also inhibited, as previously described [19]. However, phosphor-
ylation of endogenous JAK2 is not seen or inconsistently detected
in Ba/F3-BCR-JAK2 cells as it has been on Ba/F3 cells
transduced with TEL-JAK2 [27,28,40,41]. Whole cell lysates
from the same experiment were used and probed with anti-
pSTAT5 Ab to detect whether BCR-JAK2 inhibition impaired
STAT5 activation (Figure 4A, lower panel). STAT5 phosphory-
lation on Ba/F3-BCR-JAK2, Ba/F3-TEL-JAK2 and IL-3-starved
Ba/F3-mock cells was almost completely inhibited, whereas Ba/
F3-mock cells growing with IL-3 showed 40% inhibition. Bcl-xL
expression was inhibited by 40% on TG101209-treated Ba/F3-
BCR-JAK2 cells whereas on Ba/F3-mock and Ba/F3-TEL-JAK2
cells this inhibition was lower. qPCR for Bcl-xL, Osm and Socs2
transcript detection was performed on Ba/F3-mock, Ba/F3-BCR-
JAK2 and Ba/F3-TEL-JAK2 cells treated with TG101209 for
12 h. (Figure 4C). Both treated BCR-JAK2 and TEL-JAK2-
expressing cells showed inhibition of Bcl-xL, Osm and Socs2
expression. Taken together, these data suggest that TG101209
inhibited STAT5 activation and STAT5-mediated induction of
Bcl-xL, Osm and Socs2 through inhibition of both chimeric proteins
in transduced Ba/F3 cells and inhibition of endogenous JAK2 in
Ba/F3-mock cells growing with IL-3.
TG101209 induces Ba/F3-BCR-JAK2 cell death by
apoptosis
To determine whether TG101209 inhibitor induced apoptosis
of BCR-JAK2 and TEL-JAK2-expressing cells, as previously
described for cell lines bearing the JAK2V167F mutation [19],
Annexin-V binding assays were performed using flow cytometry
(Figure 5A). Treatment of Ba/F3-BCR-JAK2 cells with
TG101209 (1 mM) for 24 h resulted in an increase of approxi-
mately 80% in Annexin-V/7-AAD–positive cells. As expected,
TG101209 only showed a modest increase in apoptosis of Ba/F3
mock cells growing with IL-3 (Figure 5B), thus demonstrating that
induction of apoptosis in Ba/F3-BCR-JAK2 cells was a conse-
quence of BCR-JAK2 inhibition. The rate of apoptotic Ba/F3-
TEL-JAK2-treated cells was slightly lower than Ba/F3-BCR-
JAK2-treated cells in accordance with their reduced susceptibility
to TG101209 (Figure 4A). This could be due to higher levels of
TEL-JAK2 protein expression (Figures 3A and 4B).
Nude mice injected with Ba/F3 cells expressing BCR-JAK2
develop tumors
The oncogenic properties of leukemic fusion proteins have
already been described in a nude mice model [42]. In order to
assess the tumorigenic potential of BCR-JAK2, ten nude mice
were subcutaneously injected on the right side above the hind legs
with Ba/F3-BCR-JAK2 cells and on the left side with Ba/F3-
mock cells. Three mice died of nonrelated events and the rest were
analyzed 20 days later, when tumors were clearly observed on the
right side in all of them (Figure 6A, left panel). As expected, none
of the mice developed tumors on the left side where Ba/F3-mock
cells were injected. Considering that cells expressing BCR-JAK2
also co-express EGFP, its expression was confirmed in all tumors
using a digital photostation (Figure 6A, right panel). In contrast, no
EGFP signal was detected in the flank injected with Ba/F3 mock
cells. Tumors were disaggregated and cells were analyzed by flow
cytometry, which rendered at least 50% EGFP-expressing cells
(Figure 6B). EGFP-negative cells found in those samples could be
host accessory tumor cells as connective, epithelial and endothelial
cells, although methylation events downregulating EGFP expres-
sion on BCR-JAK2-bearing cells could not be excluded [43,44].
RT-PCR analysis on RNA isolated from three different tumors
showed specific amplification of BCR-JAK2 in every case
(Figure 6C). We therefore conclude that BCR-JAK2 conferred
oncogenic properties to Ba/F3 cells.
Primary progenitor cells transduced with BCR-JAK2 show
increased proliferation
To test whether mouse primary progenitor cells transduced with
BCR-JAK2 have increased survival, transduction of lineage
negative (Lin2) cells selected from bone marrow of Balb/c mice
was performed and in vitro expansion was carried out (Figure 7).
Lin2 cells transduced with pLZR-BJ showed an increase in
proliferation capacity compared to wild type or pLZR-mock
transduced cells. In fact, Lin2 BCR-JAK2-transduced cells lasted
longer than 3 months in vitro (data not shown) while proliferation
of control samples decreased after 30 days in culture. These data
suggest that besides the proliferative advantage and ability to
transform hematopoietic cell lines (Figure 2), BCR-JAK2
increased survival of primary hematopoietic progenitor cells.
These findings are in agreement with in vivo transforming abilities
as previously described for other leukemogenic proteins [45,46].
BCR-JAK2 Is a New Oncogenic Tyrosine-Kinase
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32451
Discussion
Two-thirds of adult patients with ALL do not have molecular
markers associated with the disease; therefore, the search for new
markers is an active area of research. We present the unique case
of a patient suffering from ALL with a complex karyotype at
diagnosis and harboring a BCR-JAK2 fusion gene. Three
additional studies report this translocation in leukemia patients.
In contrast with the case presented here, the clinical diagnoses
were found in atypical CML [9,10] and AML [11]. Our finding
indicates that this translocation is not restricted to the myeloid
lineage. Interestingly, in one of the CML-like cases, the break-
points in BCR and JAK2 were the same as in our case, whereas in
the AML case the breakpoint in BCR was similar to that of p210
BCR/ABL and was in exon 11 for JAK2. Unlike our case, the
patients in the cases mentioned above died after developing a blast
crisis.
Specially designed qPCR to detect BCR-JAK2 is a new tool for
molecular diagnosis and follow-up of MRD. In the case presented
here, persistence of undetectable MRD correlated with complete
genetic and clinical response maintained to the present day. This
could be due to the early molecular response achieved prior to
SCT [47]. Further studies and more case report data are necessary
to determine whether BCR-JAK2-positive myeloid/lymphoid
neoplasms represent a distinct clinical-pathological entity.
The BCR-JAK2 protein contains the BCR coiled-coil domain
fused to the JH1-tyrosine-kinase domain of JAK2. Native JAK2 in
normal cells is phosphorylated by oligomerization of growth factor
or cytokine receptors, whereas ligand-independent oligomerization
of receptor and non-receptor TK in leukemias and solid tumors
have been reported [15]. Therefore, in BCR-JAK2, it could be
hypothesized that the kinase domain of JAK2 was activated
through oligomerization mediated by the coiled-coil domain of
BCR, as occurred in the constitutive activation of BCR-ABL [48].
Figure 4. TG101209, a JAK2 inhibitor, down-regulates JAK2, BCR-JAK2, and STAT5 tyrosine-phosphorylation, as well as target gene
expression of Ba/F3-BCR-JAK2 transduced cells. (a) Sigmoidal dose-response curve showing viability of Ba/F3-mock growing with IL-3
(IC50 = 3180 nM) and Ba/F3-BCR-JAK2 and Ba/F3-TEL-JAK2 growing in absence of IL-3 (IC50 = 246 and 369 nM, respectively). The percentage of
growth, relative to that of cells in the absence of drug, is plotted for increasing concentrations of TG101209 (where X axis is the logarithm of
concentration). (b) Western blot analysis of transduced Ba/F3 cells treated for 12 h with 1 mM TG101209 (TG) or the vehicle (DMSO). Cellular lysates
were immunoprecipitated with anti-pTyr Ab and immunoblotted with anti-JAK2 (upper panel). Whole cell lysates were probed with anti-pSTAT5,
anti-STAT5 and anti-Bcl-xL Ab’s (bottom). The expression levels of Tubulin were used as a loading control. STAT5 levels were used as a loading control
for pSTAT5. (c) qPCR for Bcl-xL, Osm and Socs2 expression on Ba/F3-mock, Ba/F3-BCR-JAK2 and Ba/F3-TEL-JAK2 cells treated for 12 h with 1 mM
TG101209. For comparative purposes, mRNA levels in untreated cells were normalized to 1. Bars represent fold changes of each gene after
normalization with GADPH levels. Samples from three independent experiments were measured. Results are given as mean 6 SEM (n = 3).
doi:10.1371/journal.pone.0032451.g004
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Here, we report that Ba/F3 cells transformed to growth factor-
independence by BCR-JAK2 showed STAT5 phosphorylation
and translocation into the nucleus. These findings are consistent
with the reported activation of the JAK-STAT pathway in
transformed BCR-ABL and TEL-JAK2 cells, suggesting an
essential role for STAT5 in both cellular transformation and
maintenance of disease by TK fusion proteins or the Abelson
virus [49,50,51]. In normal hematopoietic cells, STAT5 is
activated by a wide variety of cytokines that promote differen-
tiation, proliferation, and suppression of apoptosis by regulating
expression or phosphorylation of BcL-2 gene family members
[32]. The anti-apoptotic effect mediated by STAT5 activation in
hematopoietic progenitors is partially based on the transcriptional
regulation of Bcl-xL gene expression in response to IL-3 [33] and
to BCR-ABL in transformed cells [35,36]. Consistent with this,
we found Bcl-xL expression on Ba/F3-BCR-JAK2 cells in the
absence of growth factor, suggesting that the JAK2/STAT5/Bcl-
xL pathway could be responsible for Ba/F3-BCR-JAK2 cell
proliferation and survival. However, we cannot exclude the
participation of the BCR moiety in these activation processes
[52,53]. Further studies to evaluate whether different partners
could modify the chimeric protein behaviour through specific
downstream signal transduction effectors would thus be of
interest. It is worth noting that Bcl-xL expression was enhanced
in the patient samples at diagnosis compared with those taken
during remission, as previously described in a variety of human
cancers, including AML [54]. Moreover, luciferase assays with
HEK293T cells showed that BCR-JAK2 has the ability to induce
the Bcl-xL promoter.
Fusion TK’s involved in leukemic processes are localized to the
cytoplasm, where they maintain activated downstream effectors.
Accordingly, we detected BCR-JAK2 protein in the cytoplasm,
while pSTAT5 was found in the nucleus of Ba/F3-BCR-JAK2
cells as previously described for Ba/F3 expressing TEL-JAK2
[28].
TG101209-treated BCR-JAK2-expressing cells impaired both
endogenous JAK2 and BCR-JAK2 phosphorylation and, conse-
quently, STAT5 activation and Bcl-xL expression, all resulting in
triggering of apoptosis. Treatment of Ba/F3-mock cells in the
presence of IL-3 showed a lower inhibition of wild type JAK2 and
Figure 5. TG101209 induces apoptosis of Ba/F3-BCR-JAK2 cells. Ba/F3-mock growing with IL-3, Ba/F3-BCR-JAK2 and Ba/F3-TEL-JAK2 cells
(105/ml) were grown in 24-well plates and treated either with DMSO or 1 mM TG101209 (TG) for 24 h. Ba/F3-mock cells growing for 24 h without IL-3
were dead (data not shown). Apoptosis was measured using flow cytometry analysis as the percentage of cells expressing annexin-V/7-AAD on the
cell surface. (a) One representative experiment out of three is shown. (b) Quantification of apoptotic cells. Results are given as mean 6 SEM (n = 3).
doi:10.1371/journal.pone.0032451.g005
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Figure 6. Nude mice injected with Ba/F3-BCR-JAK2 cells develop tumors. Mice were subcutaneously injected with 107 Ba/F3-mock cells (left
flank) and Ba/F3-BCR-JAK2 cells (right flank). (a) Left panel: white light photograph showing mice bearing a tumor only on the right side, where Ba/
F3-BCR-JAK2 cells were injected (black arrows). Right panel: EGFP+ tumor (white arrows) captured on a digital photostation showing the reflected
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STAT5 phosphorylation, as well as Bcl-xL protein expression.
Also, apoptosis was lower than in Ba/F3-BCR-JAK2-treated cells,
probably due to the anti-apoptotic role reported for IL-3
activation [36].
Finally, the usefulness of immunodeficient mice models to assess
the propagation of oncoprotein-expressing cell lines [55], and to
confirm their ability to produce tumors has been well established
[42]. Here, we have shown how Ba/F3-BCR-JAK2 cells are able
to induce tumors in nude mice, thus indicating that BCR-JAK2
has oncogenic properties. Further research will be developed to
evaluate whether mouse Lin- progenitors transduced with BCR-
JAK2 are able to induce a hematopoietic disease in lethally
irradiated recipient mice. Interestingly, this model will also serve as
a useful approach for testing new JAK2 inhibitors such as
TG101209.
Our results demonstrate that BCR-JAK2 is a hyperactive TK
with transforming and tumorigenic properties based on sustained
STAT5 activation and Bcl-xL induction leading to increased
survival. Thus, we hypothesize that BCR-JAK2 could play a
central role in the induction of lymphoproliferative disease in this
patient. Further studies are necessary to elucidate the incidence of
BCR-JAK2 fusion in the development of leukemia in the general
population. JAK2 inhibitors abrogate BCR-JAK2 function by
blocking the JAK2/STAT5 activation pathway, which in turn
leads to cell death by apoptosis. We believe that abnormal fusion
transcripts involving JAK2 should be investigated in patients with
atypical CML and acute types of leukemia. JAK2 inhibitors
warrant further investigation for use alone or in combination with
standard chemotherapy in treating human cancers with elevated
JAK2 activity.
Supporting Information
Figure S1 BCR-JAK2 breakpoint region sequence. (a) PCR
product sequence (281 bp) obtained at diagnosis with the
BCR-ABL primers used for p190 detection. Green, BCR-B
primer sequence; black, BCR (exon 1); red, JAK2 (exon 19);
blue, complementary sequence of ABL3 primer used for the
first PCR amplification. The open reading frame is maintained.
(b) Detailed sequence alignment analysis of reverse ABL3
primer (blue) showing 14 nucleotides (red) complementary to
the flanking region of JAK2 sequence shown in (a).
(TIF)
Figure S2 BCR-JAK2 is located in the cytoplasm. Immunoflu-
orescence analysis of HEK293T cells transiently transfected with
pLZR carrying BCR-JAK2 (HEK293T-BJ) or control vector
(HEK293T-mock) analyzed by confocal microscopy. Transfected
cells were detected by EGFP expression. JAK2 expression was
shown in red only in the cytoplasm of HEK293T-BJ cells. The
merged image showed nuclei stained with DAPI (blue), EGFP
(green), and anti-JAK2 Ab (red) on HEK293T-BJ transfected cells.
Scale bar = 5 mm.
(TIF)
Figure S3 Quantification of Bcl-xL expression in the samples from
the patient at diagnosis and at complete molecular remission (CMR)
for BCR-JAK2. Bars represent relative Bcl-xL levels normalized
using H3 and results are given as mean 6 SD (n = 3).
(TIF)
Figure S4 BCR-JAK2 elicited BcL-xL promoter activation.
Luciferase assay of HEK293T cells transiently co-transfected with
a plasmid bearing the promoter region of BcL-xL tagged to
luciferase (pGL2-pmter Bcl-xL 0.6R) together with plasmids coding
for either BCR-JAK2 or a constitutively active STAT5. Luciferase
activity induction was calculated as firefly/renilla luciferase activities
and normalized using control vector-transfected levels. One
representative experiment out of three is shown due to the high
variation obtained by transient transfection experiments.
(TIF)
Methods S1
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